A Phase 4 interventional study of Rasburicase in Hyperuricemia, sponsored by Sanofi. Completed at 1 site in Brazil. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2009-09-25.
Sponsored by Sanofi · Phase 4, Interventional, and Treatment
The purpose of this study is to determine whether rasburicase is effective and safety in correcting hyperuricemia.
215 studies on the registry are indexed under Hyperuricemia; 40 are open to participants now.
This study's enrollment of 33 is below the median of 64 across 172 interventional studies indexed under Hyperuricemia.
Browse Hyperuricemia studies →Sanofi is the lead sponsor of 1,508 studies on the registry; 90 are open to participants now.
Of its 198 completed or terminated interventional studies of FDA-regulated products, 118 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
List of inclusion Criteria:
List of exclusion Criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Rasburicase 0,20mg/Kg/Day once a day 3-7 days
Drug: Rasburicase
Rasburicase 0,20mg/Kg/Day once a day 3-7 days
Percentage of patients with uric acid greater-than-normal laboratory levels (hyperuricemia)
Time frame: 24-48 hours after last dose of rasburicase
Percentage of patients with uric acid greater-than-normal laboratory levels (hyperuricemia)
Time frame: 28 (+- 3) days after the last dose of rasburicase
Adverse events occurrence
Time frame: During the study
This study is completed, as verified in Sep 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tumor Lysis Syndrome
Sanofi